Equitable Access: Examining Discriminatory & Restrictive Practices in Prescription Drug Formularies

Executive Summary (Full Report - PDF) Modern formularies initially emerged in the 1980s and 1990s as tools for managing prescription drug costs within healthcare institutions. However, significant changes occurred after the passage of the Affordable Care Act (ACA) in...

Patient Group Releases Special Report: CMS vs FDA: How Medicare and Medicaid Coverage Decisions Limit Patient Access

New report analyzes the patient impact of growing coverage restrictions for FDA accelerated approval treatments. WASHINGTON — Patients Rising, a non-profit organization that champions patients with chronic and rare diseases, today released a special report titled CMS...

PRESS RELEASE: Patients Rising Calls on CMS to Engage with Patients in Drug Price Negotiations

Patients Rising, a non-profit organization advocating on behalf of patients with chronic and rare diseases, today released Principles for CMS on Harnessing the Power of Patient Involvement When Implementing the Inflation Reduction Act.

 Making effective decisions in health care requires a thorough understanding of the patient perspective, as well as robust, precise measures of response to therapy. The Patient Access & Affordability Project evaluates the various frameworks used to assess and demonstrate the value of new treatments to ensure that the patient is kept at the center of health care decisions.

Get Updates in Your Inbox

Sign Up.  Stay Informed.

The Conversation

Supreme Court Passes on Skinny Labeling Case: What Does This Mean for Patients?

Supreme Court Passes on Skinny Labeling Case: What Does This Mean for Patients?

In mid-May, the U.S. Supreme Court opted not to take up a patent-infringement case between two pharmaceutical companies – Teva and GlaxoSmithKline (GSK). While it largely went unnoticed among those who are not patent lawyers, IP nerds, or drug companies, the decision’s ripple effects could have a negative impact for patients across the country looking to get access to newer, better treatments.

read more
OP-ED: Promising New Alzheimer’s Drug Calls for CMS to Rethink Access Restrictions .

OP-ED: Promising New Alzheimer’s Drug Calls for CMS to Rethink Access Restrictions .

Some of the most exciting advances in science and medicine are happening in Alzheimer’s, a disease that is one of the greatest epidemics of this generation. Eli Lilly announced promising results last week for experimental amyloid-targeting drug donanemab. These clinical trial results showed that the drug can slow cognitive and functional decline for people with early-stage Alzheimer’s disease. 

read more